GlassScriptPhysician profile
Christopher S Thompson
NPI 1003032046
$42,373.31
in general payments reported to CMS, 2019-2025
31 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,336 · 2022: $2,576 · 2023: $3,496 · 2024: $15K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $8,023 · Food and Beverage: $7,676 · Travel and Lodging: $2,065 · Education: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,125.00 |
| Consulting Fee | $8,023.18 |
| Food and Beverage | $7,675.61 |
| Travel and Lodging | $2,064.87 |
| Education | $572.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15,495.37 | 2021-2025 | |
| Abbvie INC. | $14,170.84 | 2021-2025 | |
| Leo Pharma INC. | $2,238.42 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $1,909.75 | 2021-2025 | Opzelura |
| Regeneron Pharmaceuticals, INC. | $1,456.95 | 2025 | Dupixent |
| Regeneron Healthcare Solutions, INC. | $1,197.91 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,014.67 | 2021-2025 | Tremfya |
| Genzyme Corporation | $704.53 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $609.13 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $564.16 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $504.53 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $450.74 | 2021-2025 | Ilumya |
| Ucb, INC. | $395.75 | 2022-2025 | Bimzelx, Cimzia |
| Amgen INC. | $379.64 | 2021-2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $311.46 | 2021-2025 | Cabtreo, Jublia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $201.77 | 2021-2025 | Nemluvio, Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.64 | 2022-2025 | Spevigo |
| Dermavant Sciences, INC. | $108.42 | 2023-2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $105.15 | 2021-2022 | |
| Biofrontera INC. | $81.25 | 2021-2025 | Ameluz, Bf-Rhodoled, Rhodoled Xl |
| Journey Medical Corporation | $80.69 | 2022-2024 | |
| Merz North America, INC. | $58.96 | 2025 | |
| Arcutis Biotherapeutics, INC. | $57.37 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $28.61 | 2021 | |
| Botanix Sb INC | $27.08 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $24.71 | 2023 | |
| Verrica Pharmaceuticals INC. | $20.66 | 2023 | Ycanth |
| Epi Health, LLC | $18.15 | 2022 | |
| Almirall LLC | $16.06 | 2021 | |
| Mimedx Group, INC. | $14.60 | 2024 | |
| Organon LLC | $6.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.